Rosacea – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Rosacea – Pipeline Review, H2 2017’, provides an overview of the Rosacea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rosacea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Rosacea

The report reviews pipeline therapeutics for Rosacea by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Rosacea therapeutics and enlists all their major and minor projects

The report assesses Rosacea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Rosacea

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Rosacea

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Almirall SA

Amorepacific Corp

BioPharmX Inc

Cutanea Life Sciences Inc

ELORAC Inc

Foamix Pharmaceuticals Ltd

Hovione FarmaCiencia SA

Promius Pharma LLC

Sol-Gel Technologies Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Rosacea - Overview 7

Rosacea - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Products under Development by Companies 11

Rosacea - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Rosacea - Companies Involved in Therapeutics Development 20

Almirall SA 20

Amorepacific Corp 20

BioPharmX Inc 21

Cutanea Life Sciences Inc 21

ELORAC Inc 21

Foamix Pharmaceuticals Ltd 22

Hovione FarmaCiencia SA 22

Promius Pharma LLC 23

Sol-Gel Technologies Ltd 23

Rosacea - Drug Profiles 24

AC-701 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

ACUD-1 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

ADP-13612 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

benzoyl peroxide - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

carbamide peroxide - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

DFD-29 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

DMT-210 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

DMT-220 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

EP-0003 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

FMX-103 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

itraconazole - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

minocycline - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

minocycline - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

MSB-03 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

omiganan pentahydrochloride - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

PAC-14028 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

phenylbutyrate - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Rosacea - Dormant Projects 50

Rosacea - Discontinued Products 52

Rosacea - Product Development Milestones 53

Featured News & Press Releases 53

Jun 12, 2017: Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam

1.5% 53

Jan 18, 2017: Dermata Therapeutics Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study 53

Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients 54

Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea 54

Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea 55

May 19, 2016: Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea 55

May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study 56

May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea 56

Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea 57

Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK 57

Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission 58

Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea 58

Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso 59

Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33% 60

Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso 60

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

List of Tables

Number of Products under Development for Rosacea, H2 2017 8

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products by Stage and Target, H2 2017 13

Number of Products by Stage and Mechanism of Action, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Rosacea – Pipeline by Almirall SA, H2 2017 20

Rosacea – Pipeline by Amorepacific Corp, H2 2017 20

Rosacea – Pipeline by BioPharmX Inc, H2 2017 21

Rosacea – Pipeline by Cutanea Life Sciences Inc, H2 2017 21

Rosacea – Pipeline by ELORAC Inc, H2 2017 21

Rosacea – Pipeline by Foamix Pharmaceuticals Ltd, H2 2017 22

Rosacea – Pipeline by Hovione FarmaCiencia SA, H2 2017 22

Rosacea – Pipeline by Promius Pharma LLC, H2 2017 23

Rosacea – Pipeline by Sol-Gel Technologies Ltd, H2 2017 23

Rosacea – Dormant Projects, H2 2017 50

Rosacea – Dormant Projects, H2 2017 (Contd..1), H2 2017 51

Rosacea – Discontinued Products, H2 2017 52

List of Figures

List of Figures

Number of Products under Development for Rosacea, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products by Top 10 Targets, H2 2017 12

Number of Products by Stage and Top 10 Targets, H2 2017 12

Number of Products by Top 10 Mechanism of Actions, H2 2017 14

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports